Biotechnology

Continuity Biosciences aims to eliminate the adherence burden of HIV PrEP with a multi-year nanofluidic implant, backed by the Gates Foundation.

Parabilis Medicines advances its first-in-class beta-catenin inhibitor into a new FAP cohort, signaling a paradigm shift from surgical intervention to systemic prevention.

By out-licensing its early-stage hypophosphatasia drug, 1cBio secured non-dilutive capital to fund its proprietary oncology pipeline without the usual risks.

Modern medicine’s greatest triumphs in oncology and rheumatology are inadvertently fueling a silent surge in Secondary Immunodeficiencies.

Orum Therapeutics enters the clinic with a novel degrader-antibody conjugate, aiming to turn a historically toxic mechanism into a targeted lifeline for AML.

By building talent infrastructure before the factories even open, Ohio is aggressively positioning the Midwest to dethrone coastal biomanufacturing hubs.

The clinical-stage biotech's public debut tests investor appetite for immunology as it funds a novel Treg pipeline into 2029.

Following its 2024 Sanofi spin-off, Inhibrx Biosciences is preparing to unveil pivotal cancer trial data that could validate its multivalent protein platform.

As a new foundation offers free seminars for Thyroid Eye Disease, it highlights the complex intersection of rare disease advocacy and pharmaceutical marketing.

As Medicare ramps up scrutiny on skin substitutes, a new zero-upfront-cost biologic program promises clinical results and protection from financial ruin.

As the National Academy of Medicine's $1.5M competition concludes, a novel biologic targeting muscle loss challenges how we treat human aging.

As Novastra Therapeutics prepares to unveil Phase 1 data at ESMO, its supramolecular nanocloak could redefine how we treat checkpoint-resistant solid tumors.

Trevi Therapeutics heads to CHEST 2026 with compelling patient-reported outcomes for its IPF chronic cough drug, aiming to fill a massive clinical void.

Immuron’s Phase 2 Travelan trial missed its primary endpoint, but a 71% drop in antibiotic use has the Pentagon and microbiome experts paying close attention.

After a high-profile Phase 2 trial failure in pulmonary fibrosis, Syndax narrows its strategic focus to maximize its established cGVHD partnership with Incyte.

By proving IBSRELA reduces costly specialist visits, Ardelyx is arming itself for payer negotiations and a lucrative leap into the broader constipation market.

Odyssey Therapeutics is testing a novel combination therapy for ulcerative colitis, aiming to break the therapeutic ceiling that limits current IBD treatments.

A recent Nasdaq deficiency notice for Singapore's CytoMed Therapeutics highlights the intense market pressures facing pre-revenue biotechs today.

NurExone Biologic reports statistically significant preclinical data for its exosome therapy, taking a crucial step toward reversing optic nerve damage.

By targeting the genetic roots of BAG3 cardiomyopathy with a novel low-dose capsid, Affinia aims to solve gene therapy’s systemic toxicity bottleneck.